What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Chemotherapy
His primary areas of study are Multiple myeloma, Internal medicine, Surgery, Oncology and Bortezomib.
His studies deal with areas such as Chemotherapy, Dexamethasone and Transplantation as well as Multiple myeloma.
His Transplantation research focuses on subjects like Clinical endpoint, which are linked to Hazard ratio.
His studies examine the connections between Internal medicine and genetics, as well as such issues in Gastroenterology, with regards to Beta-2 microglobulin.
While the research belongs to areas of Surgery, Thierry Facon spends his time largely on the problem of Urology, intersecting his research to questions surrounding Induction chemotherapy.
His biological study spans a wide range of topics, including Clinical trial, Pathology, Immunology, Very Good Partial Response and Survival analysis.
His most cited work include:
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma (2415 citations)
- Bortezomib or high-dose dexamethasone for relapsed multiple myeloma (2128 citations)
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma (1211 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Multiple myeloma, Internal medicine, Oncology, Surgery and Lenalidomide.
His Multiple myeloma study incorporates themes from Newly diagnosed, Transplantation and Dexamethasone.
His research in Internal medicine intersects with topics in Gastroenterology and Immunology.
His Oncology study also includes
- Cytogenetics which connect with Bone marrow,
- Fluorescence in situ hybridization most often made with reference to Pathology.
As part of his studies on Surgery, Thierry Facon often connects relevant subjects like Urology.
His Lenalidomide study combines topics from a wide range of disciplines, such as Pediatrics, Neutropenia, Pharmacology and Phases of clinical research.
He most often published in these fields:
- Multiple myeloma (73.06%)
- Internal medicine (64.92%)
- Oncology (32.55%)
What were the highlights of his more recent work (between 2016-2021)?
- Multiple myeloma (73.06%)
- Internal medicine (64.92%)
- Oncology (32.55%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Multiple myeloma, Internal medicine, Oncology, Dexamethasone and Lenalidomide.
Thierry Facon has included themes like Newly diagnosed, Adverse effect and Transplantation in his Multiple myeloma study.
His work in Internal medicine is not limited to one particular discipline; it also encompasses Gastroenterology.
In his study, Clinical trial is strongly linked to Randomized controlled trial, which falls under the umbrella field of Dexamethasone.
His Lenalidomide research incorporates elements of Thalidomide, Survival rate, Surgery, Phases of clinical research and Clinical endpoint.
His Bortezomib research includes themes of Proteasome inhibitor and Autologous stem-cell transplantation.
Between 2016 and 2021, his most popular works were:
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study (261 citations)
- Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial (180 citations)
- Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM (145 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Chemotherapy
His main research concerns Multiple myeloma, Internal medicine, Lenalidomide, Oncology and Bortezomib.
His Multiple myeloma study incorporates themes from Interim analysis, Clinical trial, MEDLINE, Adverse effect and Transplantation.
His Internal medicine study often links to related topics such as Gastroenterology.
Thierry Facon interconnects Survival rate, Clinical endpoint, Thalidomide and Pembrolizumab in the investigation of issues within Lenalidomide.
The concepts of his Thalidomide study are interwoven with issues in Autologous stem-cell transplantation and Melphalan.
His studies deal with areas such as Prospective cohort study and Surgery as well as Bortezomib.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
